Dynavax Technologies | DVAX - Operating Expenses


Dynavax Technologies reported $81.01M in Operating Expenses for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Adma Biologics USD 79.19M 1.28M Jun/2025
Amgen USD 6.52B 337M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Dynavax Technologies USD 81.01M 10.78M Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Glaxosmithkline GBP 5.55B 1.87B Jun/2025
Merck USD 9.44B 217M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
TG Therapeutics USD 106.3M 5.93M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025